Search and analyze individual stocks with comprehensive metrics
Medinova Diagno.
Fundamental Score
Medinova Diagno. Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of MEDINOV across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (108.87%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (27.35%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 18.72 vs Industry: 40.71)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (57.14%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Excellent EPS Growth (56.49% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (56.49% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Strong Interest Coverage (6.78x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (62.14%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Healthcare Service Provider sector...
Financial Statements
Comprehensive financial data for Medinova Diagno.
About MEDINOV
Company Details
Market Information
Performance
MEDINOV Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of MEDINOV?
MEDINOV is currently trading at ₹40.10 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of MEDINOV shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of MEDINOV and what does it mean?
MEDINOV has a P/E ratio of 18.72x compared to the industry average of 40.71x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹19 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is MEDINOV performing according to Bull Run's analysis?
MEDINOV has a Bull Run fundamental score of 64.8/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: N/A%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does MEDINOV belong to?
MEDINOV operates in the Healthcare Services industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Medinova Diagno.. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for MEDINOV?
MEDINOV has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Medinova Diagno. generates profits from shareholders' equity. An ROE of N/A% means the company generates ₹N/A profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is MEDINOV's debt-to-equity ratio and what does it indicate?
MEDINOV has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk. This means the company has ₹0 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is MEDINOV's dividend yield and is it a good dividend stock?
MEDINOV offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has MEDINOV grown over the past 5 years?
MEDINOV has achieved 5-year growth rates of: Sales Growth 5.66%, Profit Growth 56.49%, and EPS Growth 56.49%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in MEDINOV and why does it matter?
Promoters hold 62.14% of MEDINOV shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does MEDINOV compare with its industry peers?
MEDINOV trades at P/E 18.72x vs industry average 40.71x, with ROE of N/A% and ROCE of 108.87%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether MEDINOV is outperforming its competitive set in profitability, growth, and valuation metrics.
What is MEDINOV's market capitalization and what category does it fall into?
MEDINOV has a market capitalization of ₹40 crores, making it a Small-cap stock. Small-cap stocks offer high growth potential but with higher volatility and risk. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for MEDINOV?
Key ratios for MEDINOV: ROE N/A% (Needs improvement), ROCE 108.87%, P/E 18.72x, Debt-to-Equity N/A, Interest Coverage 6.78x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is MEDINOV stock and what is its beta?
MEDINOV has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for MEDINOV?
MEDINOV has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹40.10, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in MEDINOV?
Key risks for MEDINOV include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: N/A), and operational challenges. The stock has a Fundamental Score of 64.8/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Healthcare Services include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is MEDINOV's operating profit margin and how has it trended?
MEDINOV has a 5-year average Operating Profit Margin (OPM) of 27.35%, which is excellent and indicates strong pricing power and cost control. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is MEDINOV's quarterly performance in terms of sales and profit growth?
MEDINOV's recent quarterly performance shows YoY Sales Growth of 9.24% and YoY Profit Growth of 57.14%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in MEDINOV?
MEDINOV has FII holding of 0.00% and DII holding of 0.00%, totaling 0.00% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.